Please ensure Javascript is enabled for purposes of website accessibility

3 Best Marijuana Stocks to Buy in March

By Zhiyuan Sun - Mar 9, 2021 at 7:08AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These are the top players in the expanding $19.6 billion U.S. marijuana market.

There are now 15 states (plus Washington, D.C.) that have legalized recreational marijuana, creating a wild west of opportunities for large dispensary chains and individual growers alike. In addition, it is possible that we could see the drug receive decriminalization at a federal level under the new Biden administration. The opportunities are endless in this promising market.

That's why it's always a good idea to invest in the best marijuana companies with established track records. The entry barrier to the marijuana industry is very high as companies are often required to control the entire supply/distribution chain before states issue them a dispensary license. Let's look at how three companies have overcome the challenge and why they can make you richer in March. 

Woman smelling marijuana plant ready for harvest.

Image Source: Getty Images.

1. Trulieve Cannabis

Trulieve Cannabis (TCNNF -1.01%) is the biggest provider of medical marijuana in Florida, with over 50% market share in the Sunshine State. It operates 78 stores nationwide, with over 500,000 patients and customers. The pot grower has a customer retention rate of 79% through its walk-in, pickup, and delivery services. 

In 2019, Trulieve brought in $252.8 million in revenue and $132.5 million in operating income less non-cash expenses (EBITDA). Last year, its revenue and EBITDA increased to $485 million and $225 million, respectively. Right now, the stock's valuation of 13 times sales puts it at the high end of what U.S. cannabis companies are trading for. 

However, given its gigantic market share and customer satisfaction, I believe Trulieve's history of spectacular growth will continue. It is rare to see a pot grower attain such a success level within just six years of operations. 

2. Jazz Pharmaceuticals 

At just 3.8 times revenue and 17.3 times free cash flow, Jazz Pharmaceuticals (JAZZ -1.02%) is the cheapest marijuana stock we have on our list. By the end of 2021, Jazz will complete its $7.2 billion acquisition of GW Pharmaceuticals (GWPH). GW Pharmaceuticals markets Epidiolex, a cannabinoid drug that can reduce the occurrence of seizures in patients with epilepsy by about 50%. Last year, the drug brought in $510 million in revenue, a sharp increase over the $296 million in sales it had in 2019.

What's more, Jazz is well-diversified. Outside of the cannabis venture, the company also has the No. 1 sleep disorder franchise (consisting of three drugs) in the nation. Additionally, it has five approvals in its oncology portfolio since 2015, mainly in treating small cell lung cancer. Jazz's core business brought in $2.36 billion in revenue in 2020 and it expects to increase that to $2.7 billion this year. This is definitely a well-rounded pharmaceutical cannabis company that you will not want to miss.

3. Jushi Holdings 

Jushi Holdings (JUSHF -6.84%) is a premium supplier of flowers, concentrates, and CBD operating 16 stores across seven states. If that doesn't seem like a lot, don't be dismayed. The company is very good at what it's doing. 

It expects to bring in up to $40 million in sales for Q1 2021 (ending March 31), representing a stunning 365% increase over the prior year's quarter. Jushi expects to further its momentum by opening an additional 10 to 12 stores in 2021.

The pot grower is well-capitalized as well, with $180 million in cash and securities and just $86 million in debt. Thus far, it also sees a 179% year-over-year increase in its e-commerce segment and welcomes up to 615 new customers to its dispensaries each day.

This year, the company expects to generate between $205 million and $255 million in revenue, compared to $80.6 million last year. Jushi is also well on its path to profitability, projecting an adjusted EBITDA of up to $50 million on top of its revenue. Its stock valuation of 11 times sales is pretty fair for that of kind growth. Hence, I would recommend avid marijuana investors add Jushi to their portfolios.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Jushi Holdings Inc. Stock Quote
Jushi Holdings Inc.
$1.77 (-6.84%) $0.13
Jazz Pharmaceuticals plc Stock Quote
Jazz Pharmaceuticals plc
$150.91 (-1.02%) $-1.55
GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc
Trulieve Cannabis Stock Quote
Trulieve Cannabis
$14.50 (-1.01%) $0.15

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.